Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Data is available to registered users only
Buy
Sell